OneMedNet Inks 3-Year Data Resale Deal with Atropos Health
Event summary
- OneMedNet signed a 3-year resale agreement with Atropos Health to integrate its regulatory-grade, AI-driven Real-World Data (RWD) into Atropos’ evidence-generation platform.
- The deal adds OneMedNet’s data to Atropos’ offerings under a fee arrangement, boosting OneMedNet’s Annual Recurring Revenue (ARR).
- OneMedNet’s multi-modal RWD, drawn from over 90 million patient journeys, will be embedded directly into Atropos’ platform.
- Atropos’ customers—health systems, life sciences organizations, and researchers—can purchase OneMedNet’s data through Atropos’ platform.
The big picture
The partnership underscores the growing demand for high-quality, multi-modal real-world data in clinical decision-making. By integrating OneMedNet’s regulatory-grade data into Atropos’ platform, the deal positions both companies to address the evidence gap in healthcare, potentially setting a new standard for data-driven clinical insights. The collaboration reflects a broader industry trend toward leveraging AI and multi-modal data to enhance evidence quality and accelerate decision-making in life sciences and healthcare.
What we're watching
- Revenue Growth
- How the 3-year subscription-based license will impact OneMedNet’s ARR and long-term revenue stability.
- Market Differentiation
- Whether OneMedNet’s multi-modal RWD can sustain its competitive edge in the evolving real-world data market.
- Partnership Expansion
- The pace at which OneMedNet can secure additional strategic partnerships to expand its commercial reach.
Related topics
